374
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility analysis of telephone-based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) patients with anxiety and depression comorbidities: an application for willingness to accept concept

ORCID Icon, , &
Pages 331-340 | Received 15 Feb 2018, Accepted 11 Oct 2018, Published online: 19 Oct 2018

References

  • Yohannes AM, Willgoss TG, Baldwin RC, et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25(12):1209–1221.
  • Mikkelsen RL, Middelboe T, Pisinger C, et al. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). Review Nordic Journal Psychiatry. 2004;58(1):65–70.
  • Wheaton AG, Ford ES, Cunningham TJ, et al. Chronic obstructive pulmonary disease, hospital visits, and comorbidities: national survey of residential care facilities, 2010. J Aging Health. 2015;27(3):480–499.
  • Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4SUPPL.):43S–56S.
  • Dickens C, Katon W, Blakemore A, et al. Does depression predict the use of urgent and unscheduled care by people with long term conditions? A systematic review with meta-analysis. J Psychosom Res. 2012;73(5):334–342.
  • Blakemore A, Dickens C, Guthrie E, et al. Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:501–512.
  • Laurin C, Labrecque M, Dupuis G, et al. Chronic obstructive pulmonary disease patients with psychiatric disorders are at greater risk of exacerbations. Psychosom Med. 2009;71(6):667–674.
  • Cafarella PA, Effing TW, Barton C, et al. Management of depression and anxiety in COPD. Eur Respir Monogr. 2013;59:144–163.
  • Association AP. 2013. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, VA, American Psychiatric Association, 2013.
  • Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD – a review. Respir Med. 2011;105(10):1422–1433.
  • Cully JA, Stanley MA, Petersen NJ, et al. Delivery of brief cognitive behavioral therapy for medically Ill patients in primary care: a pragmatic randomized clinical trial. J Gen Intern Med. 2017;32(9):1014–1024.
  • Chiles JA, Lambert MJ, Hatch AL. The impact of psychological interventions on medical cost offset: a meta-analytic review. Clin Psychol (New York). 1999;6(2):204–220.
  • Doyle C, Dunt D, Ames D, et al. Study protocol for a randomized controlled trial of telephone-delivered cognitive behavior therapy compared with befriending for treating depression and anxiety in older adults with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:327–334.
  • Borghi J. Aggregation rules for cost-benefit analysis: a health economics perspective. Health Econ. 2008;17(7):863–875.
  • Horowitz JK, McConnell KE. Willingness to accept, willingness to pay and the income effect. J Econ Behav Organ. 2003;51(4):537–545.
  • Grutters JP, Kessels AG, Dirksen CD, et al. Willingness to accept versus willingness to pay in a discrete choice experiment. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(7):1110–1119.
  • O’Brien BJ, Gertsen K, Willan AR, et al. Is there a kink in consumers’ threshold value for cost-effectiveness in health care? Health Econ. 2002;11(2):175–180.
  • Doyle C, Bhar S, Fearn M, et al. The impact of telephone-delivered cognitive behaviour therapy and befriending on mood disorders in people with chronic obstructive pulmonary disease: a randomized controlled trial. Br J Health Psychol. 2017;22(3):542–556.
  • Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):E1–E5.
  • Australian Government Department of Health and Ageing. 2009. Manual of resource items and their associated costs for use in major submissions to the Pharmaceutical Benefits Advisory Committee involving economic analyses (Version 4.0). 2015 Dec 15. Available from: http://www.pbs.gov.au/info/industry/useful-resources/manual
  • Australian Government Department of Health and Ageing. Medicare benefits schedule. 2013. 2015 Dec 15. Available from: http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/downloads
  • Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, Commonwealth of Australia, Canberra. 2013. 2015 Dec 15. Available from: http://www.pbs.gov.au/info/publication/schedule/archive
  • Department of Veteran Affairs. Fee schedules. 2013. 2015 Dec 15. Available from: http://www.dva.gov.au/providers/fee-schedules
  • AIHW. Australia’s welfare 2005. Australia’s welfare no. 7. Cat. no. AUS 65. Canberra. AIHW. 2005. 2015 Dec 15. Available from: http://www.aihw.gov.au/publication-detail/?id=6442467784
  • Department of Health and Ageing. National Hospital Cost Data Collection (NHCDC) reports. National Hospital Cost Data Collection. Round 17 cost weights, peer group report and hospital reference manual for 2012-13. Canberra. DoHA. 2015 Dec 15. Available from: https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-australian-public-hospitals-cost-report-2012
  • Australian Prudential Regulation Authority (APRA). Statistical trends in membership and benefits data tables 2015 Dec 15. Available from: http://www.apra.gov.au/PHI/PHIAC-Archive/Pages/PHIAC-Archive-Statistical-Trends.aspx
  • Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209–224.
  • Drummond MFSM, Claxton K, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Fourth ed. Oxford: Oxford University Press; 2015.
  • Faria R, Gomes M, Epstein D, et al. Guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157–1170.
  • Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405–415.
  • Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2):263–291.
  • Hoffman E. Willingness to Pay vs. Willingness to accept: legal and economic implications. Wash Univ Law Q. 1993;71:59.
  • Willan AR, O’Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Stat Med. 2001;20(21):3251–3259.
  • Hunink MG, Bult JR, de Vries J, et al. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Medical Decision Making: an International Journal of the Society for Medical Decision Making. 1998;18(3):337–346.
  • Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000;9(7):623–630.
  • Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
  • Nimdet K, Chaiyakunapruk N, Vichansavakul K, et al. Review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS One. 2015;10:4.
  • Goossens M, Rutten-van Molken MPH, Vlaeyen JWS, van der Linden S. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53(7):688–695.
  • Mead N, Lester H, Chew-Graham C, et al. Effects of befriending on depressive symptoms and distress: systematic review and meta-analysis. Br J Psychiatry. 2010;196(2):96–101.
  • Kenny P, Mahmic A, Lancsar E, et al. Diaries or questionnaires for collecting self-reported healthcare utilisation and patient cost data? CHERE Project Report No 20. 2003.
  • Chatzitheochari S, Fisher K, Gilbert E, et al. Using new technologies for time diary data collection: instrument design and data quality findings from a mixed-mode pilot survey. Soc Indic Res. 2018;137(1):379–390.
  • Jonkers CCM, Lamers F, Evers S, et al. Economic evaluation of a minimal psychological intervention in chronically ill elderly patients with minor or mild to moderate depression: a randomized trial (the DELTA-study). Int J Technol Assess Health Care. 2009;25(4):497–504.
  • Aj H, Ma S, Be L, et al. Cost-effectiveness of cognitive behaviour therapy versus talking and usual care for depressed older people in primary care. BMC Health Serv Res. 2011;11:33.
  • Titov N, Dear BF, Ali S, et al. Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of depression: a randomized controlled trial. Behav Ther. 2015;46(2):193–205.
  • Dear BF, Zou JB, Ali S, et al. Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of anxiety: a randomized controlled trial. Behav Ther. 2015;46(2):206–217.
  • Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial. Lancet. 2014;383(9913):219–225.
  • Norton G, McDonough CM, Cabral H, et al. Cost-utility of cognitive behavioral therapy for low back pain from the commercial payer perspective. Spine. 2015;40(10):725–733.
  • Brach M, Sabariego C, Herschbach P, et al. Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in chronic arthritis patients. J Public Health. 2010;32(4):547–554.
  • McCrae CS, Bramoweth AD, Williams J, et al. Impact of brief cognitive behavioral treatment for insomnia on health care utilization and costs. J Clin Sleep Med. 2014;10(2):127–135.
  • Sharpe L, Allard S, Sensky T. Five-year followup of a cognitive–behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Care Res. 2008;59(3):311–316.
  • Young L, Bradley L, Turner R. Decreases in health care resource utilization in patients with rheumatoid arthritis following a cognitive behavioral intervention. Biofeedback Self Regul. 1995;20(3):259–268.
  • Miravitlles M, Molina J, Antonio Quintano J, et al. Factors associated with depression and severe depression in patients with COPD. Respir Med. 2014;108(11):1615–1625.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.